MMP9 and ovarian carcinoma: The results showed that MEnZn‐CuO NPs significantly downregulated the expression of MMP2 and MMP9, which are indicators of cell migration, and the phenotypic assays also suggested that the drug significantly inhibited the migration ability of both ovarian cancer cell lines (Figure 3a and S1D).